Persistent effect of tocilizumab in refractory Takayasu’s arteritis (clinical observation)
Study of the interleukin 6 (IL-6) role in chronic autoimmune inflammation has led to the development of innovative treatments for various autoimmune inflammatory rheumatic diseases, including Takayasu’s arteritis (TAK). Given the important role of IL-6 in the pathogenesis of TAK and its association...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2022-05-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3158 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Study of the interleukin 6 (IL-6) role in chronic autoimmune inflammation has led to the development of innovative treatments for various autoimmune inflammatory rheumatic diseases, including Takayasu’s arteritis (TAK). Given the important role of IL-6 in the pathogenesis of TAK and its association with high clinical and laboratory activity of the disease, tocilizumab (TCZ) is recommended as a second-line drug if both glucocorticoids and basic antiinflammatory drugs are inefficient, and previous therapy with tumor necrosis factor-α (alpha) inhibitors. The article presents our own observation of the successful use of TCZ in a patient with refractory TAK. |
|---|---|
| ISSN: | 1995-4484 1995-4492 |